Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Ziopharm Oncology has received a notice of allowance for its patent claims covering the treatment of cancer using organic arsenics in combination with other agents or therapies, including the company's lead investigational product ZIO-101.
Subscribe to our email newsletter
The company believes this significantly strengthens its intellectual property platform in order to develop and ultimately commercialize ZIO-101.
“We are thrilled to have a very strong patent position for our lead product, ZIO-101, and expect more patent allowances to follow, positioning us with a very firm patent estate for both ZIO-101 and ZIO-201,” commented Dr Jonathan Lewis, CEO.
ZIO-101 is a novel organic arsenic currently in phase I clinical trials in patients with advanced cancers. Data to date suggest ZIO-101 may be active in a broad range of cancers; given at high doses, ZIO-101 has shown no significant toxicities.
The company believes that the ability to administer ZIO-101 at therapeutic doses without significant toxicity is particularly important for single agent treatment, the current clinical development focus of the company, and ultimately in combination therapy post-approval.